The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 01, 2022

Filed:

Apr. 06, 2016
Applicant:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Todd Ridky, Bryn Mawr, PA (US);

Christopher Natale, Philadelphia, PA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 8/49 (2006.01); C07D 405/04 (2006.01); C07D 491/048 (2006.01); A61P 17/06 (2006.01); A61P 17/18 (2006.01); A61P 17/14 (2006.01); A61P 17/00 (2006.01); A61P 17/16 (2006.01); C07D 221/16 (2006.01); A61Q 19/02 (2006.01); A61Q 17/04 (2006.01);
U.S. Cl.
CPC ...
C07D 405/04 (2013.01); A61K 8/49 (2013.01); A61P 17/00 (2018.01); A61P 17/06 (2018.01); A61P 17/14 (2018.01); A61P 17/16 (2018.01); A61P 17/18 (2018.01); A61Q 17/04 (2013.01); A61Q 19/02 (2013.01); C07D 221/16 (2013.01); C07D 491/048 (2013.01);
Abstract

The present invention includes compounds, compositions comprising the same, and methods using the compounds and/or compositions therein, for modulating skin pigmentation in a mammalian subject. In certain embodiments, the compounds of the invention treat or prevent skin disorders or diseases associated with hyperpigmentation in the subject. In other embodiments, the compounds of the invention act as antagonist to the non-canonical sex steroid hormone receptor GPRE1 and do not bind to a canonical nuclear estrogen receptor (ER). In yet other embodiments, the compounds of the invention comprise acts as agonists to the non-canonical sex steroid hormone receptor PAQR7 and do not bind to a canonical nuclear progesterone receptor (PR).


Find Patent Forward Citations

Loading…